Bezisterim for Long COVID Brain Fog and Fatigue

Bezisterim for Long COVID Brain Fog and Fatigue
27%16%5%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 27 • YES 16.4%
BioVie Inc. ($BIVI)
No stock close$1.57$1.42$1.26May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 18 • BIVI $1.36May 19 • BIVI $1.31May 20 • BIVI $1.35May 21 • BIVI $1.48May 22 • BIVI $1.52May 26 • BIVI $1.44May 27 • BIVI $1.48

Will this trial show a positive result on change from Baseline in performance on the Cogstate Cognition battery, Objective computerized neurocognitive testing assessing attention, sustained attention, verbal memory, verbal learning, psychomotor function and processing speed. A composite cognitive score is calculated as the mean of standardized (z-score-transformed) performance scores across the tasks. Higher composite scores indicate better cognitive performance., 12 Weeks?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle
Primary Completion
6/1/26
Study Completion
8/1/26
Sponsor
BioVie Inc.
Ticker
$BIVI
Type
Phase 2
Trial Status
Recruiting
Trial Size
208
NCT
NCT06847191
Trial Description
This study tests bezisterim for adults with long COVID brain fog and fatigue, measuring cognitive test performance after 12 weeks.